BYOT.L

Byotrol Plc
Byotrol PLC - Launch of PROCESSUS® Instrument Decontamination
14th November 2023, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3145T
Byotrol PLC
14 November 2023
 

 

 

A blue logo with a cross and a flower Description automatically generated

 

Byotrol Plc

 

("Byotrol" or the "Company")

 

Launch of PROCESSUS® Instrument Decontamination System

 

Leading antimicrobial technology company Byotrol plc (AIM:BYOT) has today announced the launch of PROCESSUS®, a 360-degree instrument decontamination system, intended for the simple and effective reprocessing of instruments and specialist equipment, in both animal and human healthcare organisations.

PROCESSUS® is the third launch of Byotrol's next-generation surface disinfectant technology, which was first introduced in November 2022, under Byotrol's market-leading ANIGENE brand and subsequently launched under the CHEMGENE brand earlier this year.

 

Instrument decontamination refers to the process of making instruments and equipment safe for use. This can be achieved by removing, deactivating, or destroying contaminants, which can range from organic dirt and debris to harmful pathogens, like viruses, bacteria, and fungi. While the pathogenic threats to good patient care may differ slightly, the fundamental principles of effective instrument decontamination remain the same in both human and animal health environments.

 

The new PROCESSUS® brand debuts at the London Vet Show on the 16th November, where Byotrol will be demonstrating the ease-of-use and flexibility of the PROCESSUS® product range to animal health professionals from its key commercial partners in veterinary, welfare and rehoming charities, and zoos and wildlife organisations.

 

The PROCESSUS® Instrument Decontamination System incorporates enzymatic cleaners, which are designed to remove organic matter prior to disinfection, using a triple enzyme formulation which protects the integrity of instruments.  Post-cleaning, PROCESSUS® Instrument Disinfectant kills bacteria, yeasts, fungi, and viruses, including multi-drug resistant pathogens as well as denaturing DNA / RNA.

 

Central to all Byotrol products, the PROCESSUS® Instrument Decontamination System is supported by rigorous testing to the latest European efficacy test methodology, specifically those required for instrument submersion. The formulation is compatible with a wide range of equipment including thermos-sensitive and fine lumened devices, nasal / fibre-optic scopes, diagnostic and orthopedic equipment, and surgical and endontic instruments.

 

David Traynor, Interim CEO of Byotrol states:

 

"The launch of Byotrol's new PROCESSUS® Instrument Decontamination System demonstrates another step forward in our plans to future-proof our portfolio for EU and UK BPR regulatory approvals. It is the third in a series of strategic portfolio updates, which strengthens our offering in both animal health and human health markets." 

 

For detailed information about the forthcoming PROCESSUS® Instrument Decontamination range and supporting product documentation please visit our commercial website, www.byotrol.com and follow the company on LinkedIn.

 

For further information contact:

 

Byotrol Plc


Dr Trevor Francis, Non- Executive Chairman

+44 (0)1925 742 000

David Traynor, Interim Chief Executive Officer

Chris Sedwell, Chief Financial Officer

 

investorrelations@byotrol.com



Cavendish Capital Markets Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash / George Dollemore - Corporate Finance


Nigel Birks / Harriet Ward - ECM




Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon                                          

 

byotrol@flagstaffcomms.com

 

 

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in animal health, human health, consumer products and facilities management sectors. Byotrol develops and commercialises innovative biocidal technologies and brands which provide targeted protection against harmful pathogens.

 

For more information about Byotrol plc please visit byotrolplc.com and follow the company on LinkedIn.

For information on Byotrol products and customers please visit byotrol.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAEFLFFSDFEA]]>
TwitterFacebookLinkedIn